Antibiotic Coverage for Staphylococcus aureus
The choice of antibiotic for Staphylococcus aureus depends critically on whether the infection is methicillin-susceptible (MSSA) or methicillin-resistant (MRSA), with beta-lactams like cefazolin being superior for MSSA and vancomycin, daptomycin, or linezolid being the mainstays for MRSA. 1
MSSA Coverage
For methicillin-susceptible S. aureus, beta-lactam antibiotics are the drugs of choice and demonstrate superior outcomes compared to vancomycin. 2
Preferred agents:
- Cefazolin - First-line option with excellent safety profile and efficacy comparable or superior to antistaphylococcal penicillins 2
- Antistaphylococcal penicillins (oxacillin, nafcillin) - Traditional first-line agents, though cefazolin is increasingly preferred 1, 3
MRSA Coverage
The antibiotic selection for MRSA varies by infection severity and location:
Outpatient Skin/Soft Tissue Infections
For outpatient purulent cellulitis or abscesses requiring antibiotics, oral options include: 4
Clindamycin 300-450 mg PO three times daily (pediatric: 10-13 mg/kg/dose every 6-8 hours, max 40 mg/kg/day) - Provides coverage for both MRSA and beta-hemolytic streptococci, though C. difficile risk is higher 4
TMP-SMX 1-2 double-strength tablets twice daily (pediatric: trimethoprim 4-6 mg/kg/dose every 12 hours) - Avoid in third trimester pregnancy and infants <2 months 4
Doxycycline 100 mg twice daily or minocycline 200 mg loading dose, then 100 mg twice daily - Contraindicated in children <8 years and pregnancy 4
Linezolid 600 mg twice daily (pediatric: 10 mg/kg/dose every 8 hours, max 600 mg/dose) - More expensive but highly effective 4
Hospitalized/Complicated Infections
For complicated skin/soft tissue infections, bacteremia, or severe infections requiring IV therapy: 4, 1
Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (pediatric: 15 mg/kg/dose every 6 hours) - Remains standard of care despite suboptimal pharmacokinetics 4, 2
Daptomycin 4 mg/kg/dose IV daily for skin infections; 6 mg/kg/dose IV daily for bacteremia/endocarditis (pediatric: 6-10 mg/kg/dose daily) - Non-inferior to vancomycin with potentially faster bactericidal activity 4, 1, 5
Linezolid 600 mg IV/PO twice daily - Particularly effective for pneumonia and complicated skin infections, with oral bioavailability allowing transition from IV 4, 5, 6
Telavancin 10 mg/kg/dose IV daily - Option for complicated skin infections, though greater nephrotoxicity than vancomycin 4, 5
Ceftobiprole - Broad-spectrum cephalosporin with MRSA activity, non-inferior to daptomycin in phase 3 trials 1, 7
Critical Management Principles
Source control is essential and includes removal of infected devices, drainage of abscesses, and surgical debridement when indicated. 1
All patients with S. aureus bacteremia require transthoracic echocardiography; transesophageal echocardiography is needed for those with persistent bacteremia, persistent fever, metastatic infection, or implantable cardiac devices. 1
Treatment duration is typically 5-10 days for uncomplicated skin infections but 4-6 weeks for bacteremia with high-risk features or endocarditis. 4, 1
Common Pitfalls
Do not use rifampin as monotherapy or adjunctive therapy for skin/soft tissue infections, as this increases resistance without improving outcomes. 4
For simple abscesses, incision and drainage alone is often adequate; antibiotics are reserved for extensive disease, systemic illness, immunosuppression, difficult-to-drain locations (face, hand, genitalia), or lack of response to drainage alone. 4
Empiric combination therapy with both vancomycin and a beta-lactam is generally unnecessary in the era of rapid diagnostic testing, as it does not improve outcomes for MRSA bacteremia. 2
Clindamycin resistance rates must be monitored locally; use only when resistance is <10% in your institution. 4